The invention provides improved T cell compositions and methods for manufacturing T cells. More particularly, the invention provides methods of T cell manufacturing that result in adoptive T cell immunotherapies with improved survival, expansion, and persistence in vivo.

The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.

The invention encompasses methods for inhibiting histamine release pathways in a companion animal, for example, felines and in treating or preventing idiopathic cystitis or interstitial cystitis. The compositions and methods of the invention include an amount of lipoic acid that is effective in inhibiting histamine release pathways in a companion animal, for example, felines and in treating or preventing idiopathic cystitis or interstitial cystitis.

An object of the present disclosure is at least to provide a technique for improving QOL of a 40-year-old or older postmenopausal woman without menopausal disorder, and the object is achieved by a composition for improving QOL of a 40-year-old or older postmenopausal woman without menopausal disorder, comprising equols.

The present disclosure relates to a systemically administered peptide delivery platform that biodistributes to the kidney or urinary tract. The disclosure further relates to methods of treating a disease of the kidney or urinary tract in a subject in need thereof.

The present disclosure relates to a systemically administered peptide delivery platform that biodistributes to the kidney or urinary tract. The disclosure further relates to methods of treating a disease of the kidney or urinary tract in a subject in need thereof.

The present invention provides a method of treating one or more sodium channel related diseases or disorders in an individual, including related symptoms. The method comprises administering to the individual a tetrahydropyridine derivative in an amount effective to treat sodium channel related diseases or disorders in individuals. These compounds are generally categorised as Ritalin related compounds. The present invention also provides compounds for use in the treatment of and also for use in the manufacture of a medicament for the treatment of sodium channel related diseases or disorders in an individual. A method is further provided for the preparation and isolation of the derivatives of the compound of the present invention.

Provided is a compound in which a group derived from chondroitin sulfate and a group derived from a steroid are covalently bonded together via a spacer represented by general formula (I). In the formula, m represents an integer of 0 or 1. Here, if m=0, R.sup.1 represents a group selected from the group consisting of electron-donating groups and steric hindrance groups. If m=1, R.sup.1 represents a group selected from the group consisting of a hydrogen atom, electron-donating groups and steric hindrance groups.

—HN—(CH.sub.2).sub.m—CHR.sup.1—CO—  (I)

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.